Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone

Metabolism: Clinical and Experimental

Volumn 57, Issue 11, 2008, Pages 1552-1557

  Derosa, Giuseppe ^a   D'Angelo, Angela ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Gravina, Alessia ^a   Fogari, Elena ^a   Maffioli, Pamela ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b G Descovich Atherosclerosis Study Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; SIBUTRAMINE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

APPETITE DEPRESSANTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; OBESITY; THIAZOLIDINEDIONES;

EID: 53649103175     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.06.010     Document Type: Article

References (34)

1. Ogden C.L., Yanovski S.Z., Carroll M.D., et al. The epidemiology of obesity. Gastroenterology 132 (2007) 2087-2102
2. Keller U. From obesity to diabetes. Int J Vitam Nutr Res 76 (2006) 172-177
3. American Diabetes Association. Nutrition principles and recommendations in diabetes. Diabetes Care 27 S1 (2004) 36-46
4. American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care 27 S1 (2004) 58-62
5. Lee M., and Aronne L.J. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 99 (2007) 68B-79B
6. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147 (2007) 386-399
7. Jacob A.N., Salinas K., Adams-Huet B., et al. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 9 (2007) 386-393
8. Bogacka I., Gettys T.W., de Jonge L., et al. The effect of beta-adrenergic and peroxisome proliferator-activated receptor-gamma stimulation on target genes related to lipid metabolism in human subcutaneous adipose tissue. Diabetes Care 30 (2007) 1179-1186
9. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus: a position statement of American Diabetes Association. Diabetes Care 30 (2007) S48-S65
10. American Diabetes Association. Screening for diabetes (position statement). Diabetes Care 24 Suppl (2001) S21-S24
11. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity (1997), WHO, Geneva
12. Derosa G., D'Angelo A., Ragonesi P.D., et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 31 (2006) 375-383
13. Derosa G., D'Angelo A., Ragonesi P.D., et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J 37 (2007) 79-86
14. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
15. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
16. Winer B.J. Statistical principles in experimental design. 2nd ed. (1971), McGraw-Hill, New York
17. Fujioka K. Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options. Obes Res 10 Suppl 2 (2002) 116S-123S
18. Padwal R.S., and Majumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369 (2007) 71-77
19. Derosa G., Cicero A.F., Murdolo G., et al. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 17 (2004) 222-229
20. Eguchi K., Tomizawa H., Ishikawa J., et al. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res 30 (2007) 23-30
21. Derosa G., D'Angelo A., Ragonesi P.D., et al. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res 34 (2006) 545-555
22. Wilcox R., Bousser M.G., Betteridge D.J., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007) 865-873
23. Pfutzner A., Weber M.M., and Forst T. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects. Expert Opin Pharmacother 8 (2007) 1985-1998
24. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 166 (2002) 1307-1308
25. Birkenfeld A.L., Schroeder C., Boschmann M., et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106 (2002) 2459-2465
26. Narkiewicz K. Sibutramine and its cardiovascular profile. Int J Obes Relat Metab Disord 26 Suppl 4 (2002) S38-S41
27. Derosa G., Cicero A.F., Murdolo G., et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 7 (2005) 47-55
28. Sramek J.J., Leibowitz M.T., Weinstein S.P., et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by betaadrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 16 (2002) 13-19
29. McMahon F.G., Weinstein S.P., Rowe E., et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16 (2002) 5-11
30. Barnett A., Allsworth J., Jameson K., et al. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin 23 (2007) 1493-1507
31. Devchand P.R. Glitazones and the cardiovascular system. Curr Opin Endocrinol Diabetes Obes 15 (2008) 188-192
32. Diamant M., and Heine R.J. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63 (2003) 1373-1405
33. Stumvoll M. Thiazolidinediones-some recent developments. Expert Opin Investig Drugs 12 (2003) 1179-1187
34. Derosa G., Fogari E., Cicero A.F., et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 30 (2007) 387-394